SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19
<p><strong>Background</strong></p> <p>Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived from the B cells of an infected host. They are being investigated as a potential therapy for coronavirus disease 2019 (COVID‐19).</p> <p><strong&...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Cochrane Collaboration
2021
|